Immunoscintigraphy for Lung Cancer Detection
Author Information
Author(s): P. Bourguet, L. Dazord, B. Desrues, B. Collet, M.P. Ramee, P. Delaval, A. Martin, Y. Logeais, A. Pelletier, L. Toujas, D. Bourel, J. Kernec, J.C. Saccavini, M. Kremer, J.Y. Herryl
Primary Institution: Centre Eugene Marquis, Rennes
Hypothesis
Is the monoclonal antibody Po66 more effective than unrelated immunoglobulin for imaging non-small cell lung carcinoma?
Conclusion
Immunoscintigraphy using the monoclonal antibody Po66 detected 78% of primary lung tumors and 100% of recurrences.
Supporting Evidence
- Immunoscintigraphy detected 78% of primary tumors.
- 100% of recurrences were identified using the antibody.
- The localization index for the specific antibody was three times higher than for unrelated immunoglobulin.
- Immunoscintigraphy was more effective than chest X-ray for detecting local recurrences.
- Four patients had tumor spread visualized that was missed by CT scans.
Takeaway
Doctors used a special antibody to find lung cancer in patients, and it worked really well, spotting most tumors.
Methodology
Patients with confirmed lung cancer received injections of the radiolabelled monoclonal antibody Po66, and imaging was performed to assess tumor localization.
Limitations
Some tumors were not visualized by immunoscintigraphy despite being present radiologically, and poor tumor vascularization limited detection.
Participant Demographics
29 males and 1 female, aged 42 to 77 years.
Want to read the original?
Access the complete publication on the publisher's website